Breast Cancer

SAN ANTONIO – Adjuvant bevacizumab does not further improve the already very good outcomes being achieved with contemporary therapy in high-risk HER2-positive breast cancer, according to results of the randomized, phase III BETH trial.

There was little room for improvement on chemotherapy and HER2-targeted therapy with trastuzumab as the standard of care, as an estimated 92% of patients were still alive and free of disease after a median follow-up of about 3 years, lead investigator Dr. Dennis J. Slamon reported at the San Antonio Breast Cancer Symposium.

"The addition of bevacizumab didn’t add any efficacy but certainly added some safety concerns," Dr. Slamon commented in a press briefing. Increased rates of grade 3/4 adverse events, such as hypertension and bowel perforation, were associated with use of bevacizumab.

BETH thus joins a host of trials with negative results for antiangiogenic therapy in breast cancer, he said. "Unless there is a new drug or strategy where we can find the subgroup [that benefits], I think this is not going anywhere. We have gotten a pretty good effect with what we have. We have very little room at the top. We have to think about new strategies for those patients who aren’t getting the benefit that we hope they will with targeted therapy."

In other trial findings, there were consistently high rates of invasive disease–free survival regardless of whether the chemotherapy/trastuzumab regimen used (left up to the treating centers) did not contain an anthracycline (docetaxel, carboplatin, and trastuzumab [Herceptin] – TCH) or did contain an anthracycline (5-fluorouracil, epirubicin, and cyclophosphamide – FEC).

Given the known toxicity of anthracyclines and the availability of an equally effective and safer alternative, their use in HER2-positive breast cancer is no longer justified, according to Dr. Slamon, director of clinical/translational research at the University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center and professor of medicine and chief of the division of hematology/oncology at UCLA.

Acknowledging that the topic is intensely debated, Dr. Slamon noted that "there is no reason to take that risk now that we have more than 4,000 patients treated [with TCH] between BCIRG-006 [which first rigorously tested this regimen] and BETH that show that this gives a pretty favorable outcome. We at our institution do not use these drugs [anthracyclines]. It doesn’t mean they are not effective; they just don’t provide any incremental benefit over other drugs that would give you the same effect without the safety concerns."

While praising the trial as "exceptionally well run" and agreeing on interpretation of the bevacizumab results, press briefing moderator Dr. Jennifer Litton expressed an opposing view.

"I’m totally on the other side of the aisle, that we shouldn’t say that all anthracyclines should go away," maintained Dr. Litton, associate professor in the department of breast medical oncology at the University of Texas MD Anderson Cancer Center in Houston. "The BETH trial specifically asked the question: Does bevacizumab add anything? And the answer quite clearly is no." It did it compare an anthracycline- and a non–anthracycline-containing arm. "That was not the design or intent," she said.

Additionally, in contrast to other similar trials, almost half of the patients who participated in BETH had stage I disease, raising the possibility of selection bias for who received TCH.

"But I do feel that the Herceptin story and the combination stories to come" with lapatinib, pertuzumab, and TDM1 "are really going to also be the landscape changers in HER2 disease," Dr. Litton concluded. "And we are going to be continuing to find specific strategies and not a one-therapy-fits-all for all HER2 disease because we are learning more and more about the molecular subsets of cancer. How we have broken them up into triple receptors is really going to go by the wayside."

Bevacizumab (Avastin) is an antibody to vascular endothelial growth factor (VEGF). It is approved for use by the Food and Drug Administration to treat colorectal cancer, glioblastoma, non–small cell lung cancer, and renal cell cancer.

The 3,509 women enrolled in BETH (Bevacizumab and Trastuzumab Adjuvant Therapy in HER2-Positive Breast Cancer) had HER2-positive, node-positive, or high-risk node-negative breast cancer; 92% received TCH as their chemotherapy.

With a median follow-up of 38 months in the trial population overall, there was no significant difference between patients randomized to receive bevacizumab and those who did not in terms of the 3-year rate of invasive disease–free survival (92% vs. 92%) and overall survival (97% vs. 96%).

The findings were consistent across subgroups stratified by a variety of patient and disease characteristics, Dr. Slamon noted.

Additionally, the rate of invasive disease–free survival was statistically indistinguishable with or without bevacizumab in both the cohort given TCH (92% vs. 92%) and the cohort given FEC (91% vs. 89%).

In the trial population overall, addition of bevacizumab to chemotherapy tripled the rate of all grade 3/4 adverse events of special interest (27% vs. 8%, P less than .0001), such as hypertension, congestive heart failure, and gastrointestinal perforation.

Dr. Slamon disclosed that he serves as an adviser to Roche/Genentech, which supported the trial.

SAN ANTONIO – Adjuvant bevacizumab does not further improve the already very good outcomes being achieved with contemporary therapy in high-risk HER2-positive breast cancer, according to results of the randomized, phase III BETH trial.

There was little room for improvement on chemotherapy and HER2-targeted therapy with trastuzumab as the standard of care, as an estimated 92% of patients were still alive and free of disease after a median follow-up of about 3 years, lead investigator Dr. Dennis J. Slamon reported at the San Antonio Breast Cancer Symposium.

"The addition of bevacizumab didn’t add any efficacy but certainly added some safety concerns," Dr. Slamon commented in a press briefing. Increased rates of grade 3/4 adverse events, such as hypertension and bowel perforation, were associated with use of bevacizumab.

BETH thus joins a host of trials with negative results for antiangiogenic therapy in breast cancer, he said. "Unless there is a new drug or strategy where we can find the subgroup [that benefits], I think this is not going anywhere. We have gotten a pretty good effect with what we have. We have very little room at the top. We have to think about new strategies for those patients who aren’t getting the benefit that we hope they will with targeted therapy."

In other trial findings, there were consistently high rates of invasive disease–free survival regardless of whether the chemotherapy/trastuzumab regimen used (left up to the treating centers) did not contain an anthracycline (docetaxel, carboplatin, and trastuzumab [Herceptin] – TCH) or did contain an anthracycline (5-fluorouracil, epirubicin, and cyclophosphamide – FEC).

Given the known toxicity of anthracyclines and the availability of an equally effective and safer alternative, their use in HER2-positive breast cancer is no longer justified, according to Dr. Slamon, director of clinical/translational research at the University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center and professor of medicine and chief of the division of hematology/oncology at UCLA.

Acknowledging that the topic is intensely debated, Dr. Slamon noted that "there is no reason to take that risk now that we have more than 4,000 patients treated [with TCH] between BCIRG-006 [which first rigorously tested this regimen] and BETH that show that this gives a pretty favorable outcome. We at our institution do not use these drugs [anthracyclines]. It doesn’t mean they are not effective; they just don’t provide any incremental benefit over other drugs that would give you the same effect without the safety concerns."

While praising the trial as "exceptionally well run" and agreeing on interpretation of the bevacizumab results, press briefing moderator Dr. Jennifer Litton expressed an opposing view.

"I’m totally on the other side of the aisle, that we shouldn’t say that all anthracyclines should go away," maintained Dr. Litton, associate professor in the department of breast medical oncology at the University of Texas MD Anderson Cancer Center in Houston. "The BETH trial specifically asked the question: Does bevacizumab add anything? And the answer quite clearly is no." It did it compare an anthracycline- and a non–anthracycline-containing arm. "That was not the design or intent," she said.

Additionally, in contrast to other similar trials, almost half of the patients who participated in BETH had stage I disease, raising the possibility of selection bias for who received TCH.

"But I do feel that the Herceptin story and the combination stories to come" with lapatinib, pertuzumab, and TDM1 "are really going to also be the landscape changers in HER2 disease," Dr. Litton concluded. "And we are going to be continuing to find specific strategies and not a one-therapy-fits-all for all HER2 disease because we are learning more and more about the molecular subsets of cancer. How we have broken them up into triple receptors is really going to go by the wayside."

Bevacizumab (Avastin) is an antibody to vascular endothelial growth factor (VEGF). It is approved for use by the Food and Drug Administration to treat colorectal cancer, glioblastoma, non–small cell lung cancer, and renal cell cancer.

The 3,509 women enrolled in BETH (Bevacizumab and Trastuzumab Adjuvant Therapy in HER2-Positive Breast Cancer) had HER2-positive, node-positive, or high-risk node-negative breast cancer; 92% received TCH as their chemotherapy.

With a median follow-up of 38 months in the trial population overall, there was no significant difference between patients randomized to receive bevacizumab and those who did not in terms of the 3-year rate of invasive disease–free survival (92% vs. 92%) and overall survival (97% vs. 96%).

The findings were consistent across subgroups stratified by a variety of patient and disease characteristics, Dr. Slamon noted.

Additionally, the rate of invasive disease–free survival was statistically indistinguishable with or without bevacizumab in both the cohort given TCH (92% vs. 92%) and the cohort given FEC (91% vs. 89%).

In the trial population overall, addition of bevacizumab to chemotherapy tripled the rate of all grade 3/4 adverse events of special interest (27% vs. 8%, P less than .0001), such as hypertension, congestive heart failure, and gastrointestinal perforation.

Dr. Slamon disclosed that he serves as an adviser to Roche/Genentech, which supported the trial.

SAN ANTONIO – Adjuvant bevacizumab does not further improve the already very good outcomes being achieved with contemporary therapy in high-risk HER2-positive breast cancer, according to results of the randomized, phase III BETH trial.

There was little room for improvement on chemotherapy and HER2-targeted therapy with trastuzumab as the standard of care, as an estimated 92% of patients were still alive and free of disease after a median follow-up of about 3 years, lead investigator Dr. Dennis J. Slamon reported at the San Antonio Breast Cancer Symposium.

"The addition of bevacizumab didn’t add any efficacy but certainly added some safety concerns," Dr. Slamon commented in a press briefing. Increased rates of grade 3/4 adverse events, such as hypertension and bowel perforation, were associated with use of bevacizumab.

BETH thus joins a host of trials with negative results for antiangiogenic therapy in breast cancer, he said. "Unless there is a new drug or strategy where we can find the subgroup [that benefits], I think this is not going anywhere. We have gotten a pretty good effect with what we have. We have very little room at the top. We have to think about new strategies for those patients who aren’t getting the benefit that we hope they will with targeted therapy."

In other trial findings, there were consistently high rates of invasive disease–free survival regardless of whether the chemotherapy/trastuzumab regimen used (left up to the treating centers) did not contain an anthracycline (docetaxel, carboplatin, and trastuzumab [Herceptin] – TCH) or did contain an anthracycline (5-fluorouracil, epirubicin, and cyclophosphamide – FEC).

Given the known toxicity of anthracyclines and the availability of an equally effective and safer alternative, their use in HER2-positive breast cancer is no longer justified, according to Dr. Slamon, director of clinical/translational research at the University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center and professor of medicine and chief of the division of hematology/oncology at UCLA.

Acknowledging that the topic is intensely debated, Dr. Slamon noted that "there is no reason to take that risk now that we have more than 4,000 patients treated [with TCH] between BCIRG-006 [which first rigorously tested this regimen] and BETH that show that this gives a pretty favorable outcome. We at our institution do not use these drugs [anthracyclines]. It doesn’t mean they are not effective; they just don’t provide any incremental benefit over other drugs that would give you the same effect without the safety concerns."

While praising the trial as "exceptionally well run" and agreeing on interpretation of the bevacizumab results, press briefing moderator Dr. Jennifer Litton expressed an opposing view.

"I’m totally on the other side of the aisle, that we shouldn’t say that all anthracyclines should go away," maintained Dr. Litton, associate professor in the department of breast medical oncology at the University of Texas MD Anderson Cancer Center in Houston. "The BETH trial specifically asked the question: Does bevacizumab add anything? And the answer quite clearly is no." It did it compare an anthracycline- and a non–anthracycline-containing arm. "That was not the design or intent," she said.

Additionally, in contrast to other similar trials, almost half of the patients who participated in BETH had stage I disease, raising the possibility of selection bias for who received TCH.

"But I do feel that the Herceptin story and the combination stories to come" with lapatinib, pertuzumab, and TDM1 "are really going to also be the landscape changers in HER2 disease," Dr. Litton concluded. "And we are going to be continuing to find specific strategies and not a one-therapy-fits-all for all HER2 disease because we are learning more and more about the molecular subsets of cancer. How we have broken them up into triple receptors is really going to go by the wayside."

Bevacizumab (Avastin) is an antibody to vascular endothelial growth factor (VEGF). It is approved for use by the Food and Drug Administration to treat colorectal cancer, glioblastoma, non–small cell lung cancer, and renal cell cancer.

The 3,509 women enrolled in BETH (Bevacizumab and Trastuzumab Adjuvant Therapy in HER2-Positive Breast Cancer) had HER2-positive, node-positive, or high-risk node-negative breast cancer; 92% received TCH as their chemotherapy.

With a median follow-up of 38 months in the trial population overall, there was no significant difference between patients randomized to receive bevacizumab and those who did not in terms of the 3-year rate of invasive disease–free survival (92% vs. 92%) and overall survival (97% vs. 96%).

The findings were consistent across subgroups stratified by a variety of patient and disease characteristics, Dr. Slamon noted.

Additionally, the rate of invasive disease–free survival was statistically indistinguishable with or without bevacizumab in both the cohort given TCH (92% vs. 92%) and the cohort given FEC (91% vs. 89%).

In the trial population overall, addition of bevacizumab to chemotherapy tripled the rate of all grade 3/4 adverse events of special interest (27% vs. 8%, P less than .0001), such as hypertension, congestive heart failure, and gastrointestinal perforation.

Dr. Slamon disclosed that he serves as an adviser to Roche/Genentech, which supported the trial.

SAN ANTONIO – The aromatase inhibitor anastrozole has emerged as a major new agent for the primary prevention of breast cancer in high-risk postmenopausal women on the strength of a 53% reduction relative to placebo in the IBIS-II trial.

"Our results provide substantial support for the use of anastrozole as the treatment of first choice for prevention of breast cancer in high-risk postmenopausal women," Jack Cuzick, Ph.D., declared in presenting the study results at the San Antonio Breast Cancer Symposium.

IBIS-II (the International Breast Cancer Intervention Study II) was an 16-country, double-blind, randomized, placebo-controlled trial in which 3,864 postmenopausal women aged 40-70 years at high risk for breast cancer were randomized to 1 mg of oral anastrozole (Arimidex) or placebo daily for 5 years.

At 7 years of follow-up, the cumulative incidence of all breast cancers in an intent-to-treat analysis was 5.6% with placebo and 2.8% in the anastrozole group, for a highly significant 53% reduction in risk. This translates into a number needed to treat of 36; that is, it’s estimated that treating 36 women for 5 years will prevent one breast cancer in 7 years.

The incidence of estrogen receptor–positive invasive breast cancer was 3.3% in controls, compared with 1.4% with anastrozole, for a 58% relative risk reduction, added Dr. Cuzick, head of the Cancer Research U.K. Center for Cancer Prevention and director of the Wolfson Institute of Preventive Medicine at Queen Mary University of London.

The incidence of high-grade tumors was 35% lower in the anastrozole group. With additional years of follow-up, this will probably translate into a reduction in deaths from breast cancer in the anastrozole group. The plan is for at least 10 years of follow-up in IBIS-II.

Among women on placebo, 72% completed 5 years, as did 68% assigned to anastrozole.

"One of the most important findings of this trial is that the drug was very well tolerated, with only an absolute 4% difference in compliance. So drug side effects didn’t influence compliance in any major way," Dr. Cuzick observed.

The incidence of other cancers was 3.6% with placebo and 2.1% with anastrozole, for a significant 42% relative risk reduction. This was mostly driven by markedly fewer cases of skin cancer and colorectal cancer in patients on the aromatase inhibitor.

"We don’t really understand this. It’s another exciting possibility – that this drug may have an effect in reducing the risk of other cancers – which we will continue to explore," he continued.

Going into the trial, the anastrozole side effect of chief concern was fractures, but under the study protocol all participants had a baseline bone mineral density scan and were placed on a bisphosphonate if indicated. That’s presumably the explanation for the finding that the incidence of fractures didn’t differ significantly between the two study arms.

Musculoskeletal pain was reported by 64% of anastrozole-treated patients and 58% on placebo. The incidence of moderate musculoskeletal pain was 22% with anastrozole and 19% with placebo, while severe pain was reported by 8% of women in the anastrozole group, compared with 6% on placebo.

Pointing to the 58% incidence of musculoskeletal side effects in the placebo group, Dr. Cuzick said that "there’s a general perception that the aromatase inhibitors are very toxic and cause a lot of aches and pains. But 90% of the aches and pains in this study had nothing to do with the drug. They’re just a reflection of the fact that in the postmenopausal years women do get aches and pains."

Vasomotor symptoms occurred in 49% of the placebo group and 57% of women on anastrozole, a statistically significant difference.

Dr. Cuzick said that he believes the sharp reduction in breast cancer seen with anastrozole in IBIS-II is probably a class effect common to the other aromatase inhibitors. In the MAP.3 trial, an earlier study with shorter follow-up (N. Engl. J. Med. 2011;364:2381-91), exemestane showed results similar to those seen in IBIS-II. He added that the greater size and duration of IBIS-II, coupled with the fact that contralateral breast cancer rates continue to be lower at 10 years of follow-up in the anastrozole breast cancer treatment trials, makes him "quite confident" in declaring anastrozole to be the drug of first choice for prevention.

Audience member Dr. Pamela J. Goodwin rose to take issue with that assertion. She noted that there are two approved agents for this indication – tamoxifen and raloxifene – yet placebo was used as the comparator in IBIS-II.

"The evidence is indirect evidence," Dr. Cuzick replied. "Anastrozole and exemestane have shown very, very similar results. The aromatase inhibitors show larger risk reductions than tamoxifen or raloxifene, and overall serious side effects are substantially less. For that reason we think they are the appropriate first choice."

"Those are cross-trial comparisons. I’m not sure I would go that far," retorted Dr. Goodwin, professor of medicine at the University of Toronto.

In a press conference announcing the IBIS-II results, Dr. Cuzick noted that neither tamoxifen nor raloxifene is widely utilized for primary prevention of breast cancer. More public education is in order, he added.

"I think there’s a lot to be done to model what the cardiologists have done: They’ve convinced people that high cholesterol and high blood pressure are actually diseases. In fact, they’re only risk factors, but by taking drugs to reduce those risk factors there’s been a major effect. We need to make people aware there are effective ways of reducing the risk of breast cancer by more than 50%. The toxicities are limited, and if you have toxicity you simply stop treatment," he said.

The IBIS-II study was funded by Cancer Research U.K., the National Health and Medical Research Council of Australia, AstraZeneca, and Sanofi-Aventis. Dr. Cuzick is on the speaker’s bureau for AstraZeneca.

Simultaneous with Dr. Cuzick’s presentation in San Antonio, the IBIS-II results were published online in the Lancet (2013 Dec. 12 [doi:10.1016/S0140-6736(13)62292-8]).

bjancin@frontlinemedcom.com

SAN ANTONIO – The aromatase inhibitor anastrozole has emerged as a major new agent for the primary prevention of breast cancer in high-risk postmenopausal women on the strength of a 53% reduction relative to placebo in the IBIS-II trial.

"Our results provide substantial support for the use of anastrozole as the treatment of first choice for prevention of breast cancer in high-risk postmenopausal women," Jack Cuzick, Ph.D., declared in presenting the study results at the San Antonio Breast Cancer Symposium.

IBIS-II (the International Breast Cancer Intervention Study II) was an 16-country, double-blind, randomized, placebo-controlled trial in which 3,864 postmenopausal women aged 40-70 years at high risk for breast cancer were randomized to 1 mg of oral anastrozole (Arimidex) or placebo daily for 5 years.

At 7 years of follow-up, the cumulative incidence of all breast cancers in an intent-to-treat analysis was 5.6% with placebo and 2.8% in the anastrozole group, for a highly significant 53% reduction in risk. This translates into a number needed to treat of 36; that is, it’s estimated that treating 36 women for 5 years will prevent one breast cancer in 7 years.

The incidence of estrogen receptor–positive invasive breast cancer was 3.3% in controls, compared with 1.4% with anastrozole, for a 58% relative risk reduction, added Dr. Cuzick, head of the Cancer Research U.K. Center for Cancer Prevention and director of the Wolfson Institute of Preventive Medicine at Queen Mary University of London.

The incidence of high-grade tumors was 35% lower in the anastrozole group. With additional years of follow-up, this will probably translate into a reduction in deaths from breast cancer in the anastrozole group. The plan is for at least 10 years of follow-up in IBIS-II.

Among women on placebo, 72% completed 5 years, as did 68% assigned to anastrozole.

"One of the most important findings of this trial is that the drug was very well tolerated, with only an absolute 4% difference in compliance. So drug side effects didn’t influence compliance in any major way," Dr. Cuzick observed.

The incidence of other cancers was 3.6% with placebo and 2.1% with anastrozole, for a significant 42% relative risk reduction. This was mostly driven by markedly fewer cases of skin cancer and colorectal cancer in patients on the aromatase inhibitor.

"We don’t really understand this. It’s another exciting possibility – that this drug may have an effect in reducing the risk of other cancers – which we will continue to explore," he continued.

Going into the trial, the anastrozole side effect of chief concern was fractures, but under the study protocol all participants had a baseline bone mineral density scan and were placed on a bisphosphonate if indicated. That’s presumably the explanation for the finding that the incidence of fractures didn’t differ significantly between the two study arms.

Musculoskeletal pain was reported by 64% of anastrozole-treated patients and 58% on placebo. The incidence of moderate musculoskeletal pain was 22% with anastrozole and 19% with placebo, while severe pain was reported by 8% of women in the anastrozole group, compared with 6% on placebo.

Pointing to the 58% incidence of musculoskeletal side effects in the placebo group, Dr. Cuzick said that "there’s a general perception that the aromatase inhibitors are very toxic and cause a lot of aches and pains. But 90% of the aches and pains in this study had nothing to do with the drug. They’re just a reflection of the fact that in the postmenopausal years women do get aches and pains."

Vasomotor symptoms occurred in 49% of the placebo group and 57% of women on anastrozole, a statistically significant difference.

Dr. Cuzick said that he believes the sharp reduction in breast cancer seen with anastrozole in IBIS-II is probably a class effect common to the other aromatase inhibitors. In the MAP.3 trial, an earlier study with shorter follow-up (N. Engl. J. Med. 2011;364:2381-91), exemestane showed results similar to those seen in IBIS-II. He added that the greater size and duration of IBIS-II, coupled with the fact that contralateral breast cancer rates continue to be lower at 10 years of follow-up in the anastrozole breast cancer treatment trials, makes him "quite confident" in declaring anastrozole to be the drug of first choice for prevention.

Audience member Dr. Pamela J. Goodwin rose to take issue with that assertion. She noted that there are two approved agents for this indication – tamoxifen and raloxifene – yet placebo was used as the comparator in IBIS-II.

"The evidence is indirect evidence," Dr. Cuzick replied. "Anastrozole and exemestane have shown very, very similar results. The aromatase inhibitors show larger risk reductions than tamoxifen or raloxifene, and overall serious side effects are substantially less. For that reason we think they are the appropriate first choice."

"Those are cross-trial comparisons. I’m not sure I would go that far," retorted Dr. Goodwin, professor of medicine at the University of Toronto.

In a press conference announcing the IBIS-II results, Dr. Cuzick noted that neither tamoxifen nor raloxifene is widely utilized for primary prevention of breast cancer. More public education is in order, he added.

"I think there’s a lot to be done to model what the cardiologists have done: They’ve convinced people that high cholesterol and high blood pressure are actually diseases. In fact, they’re only risk factors, but by taking drugs to reduce those risk factors there’s been a major effect. We need to make people aware there are effective ways of reducing the risk of breast cancer by more than 50%. The toxicities are limited, and if you have toxicity you simply stop treatment," he said.

The IBIS-II study was funded by Cancer Research U.K., the National Health and Medical Research Council of Australia, AstraZeneca, and Sanofi-Aventis. Dr. Cuzick is on the speaker’s bureau for AstraZeneca.

Simultaneous with Dr. Cuzick’s presentation in San Antonio, the IBIS-II results were published online in the Lancet (2013 Dec. 12 [doi:10.1016/S0140-6736(13)62292-8]).

bjancin@frontlinemedcom.com

SAN ANTONIO – The aromatase inhibitor anastrozole has emerged as a major new agent for the primary prevention of breast cancer in high-risk postmenopausal women on the strength of a 53% reduction relative to placebo in the IBIS-II trial.

"Our results provide substantial support for the use of anastrozole as the treatment of first choice for prevention of breast cancer in high-risk postmenopausal women," Jack Cuzick, Ph.D., declared in presenting the study results at the San Antonio Breast Cancer Symposium.

IBIS-II (the International Breast Cancer Intervention Study II) was an 16-country, double-blind, randomized, placebo-controlled trial in which 3,864 postmenopausal women aged 40-70 years at high risk for breast cancer were randomized to 1 mg of oral anastrozole (Arimidex) or placebo daily for 5 years.

At 7 years of follow-up, the cumulative incidence of all breast cancers in an intent-to-treat analysis was 5.6% with placebo and 2.8% in the anastrozole group, for a highly significant 53% reduction in risk. This translates into a number needed to treat of 36; that is, it’s estimated that treating 36 women for 5 years will prevent one breast cancer in 7 years.

The incidence of estrogen receptor–positive invasive breast cancer was 3.3% in controls, compared with 1.4% with anastrozole, for a 58% relative risk reduction, added Dr. Cuzick, head of the Cancer Research U.K. Center for Cancer Prevention and director of the Wolfson Institute of Preventive Medicine at Queen Mary University of London.

The incidence of high-grade tumors was 35% lower in the anastrozole group. With additional years of follow-up, this will probably translate into a reduction in deaths from breast cancer in the anastrozole group. The plan is for at least 10 years of follow-up in IBIS-II.

Among women on placebo, 72% completed 5 years, as did 68% assigned to anastrozole.

"One of the most important findings of this trial is that the drug was very well tolerated, with only an absolute 4% difference in compliance. So drug side effects didn’t influence compliance in any major way," Dr. Cuzick observed.

The incidence of other cancers was 3.6% with placebo and 2.1% with anastrozole, for a significant 42% relative risk reduction. This was mostly driven by markedly fewer cases of skin cancer and colorectal cancer in patients on the aromatase inhibitor.

"We don’t really understand this. It’s another exciting possibility – that this drug may have an effect in reducing the risk of other cancers – which we will continue to explore," he continued.

Going into the trial, the anastrozole side effect of chief concern was fractures, but under the study protocol all participants had a baseline bone mineral density scan and were placed on a bisphosphonate if indicated. That’s presumably the explanation for the finding that the incidence of fractures didn’t differ significantly between the two study arms.

Musculoskeletal pain was reported by 64% of anastrozole-treated patients and 58% on placebo. The incidence of moderate musculoskeletal pain was 22% with anastrozole and 19% with placebo, while severe pain was reported by 8% of women in the anastrozole group, compared with 6% on placebo.

Pointing to the 58% incidence of musculoskeletal side effects in the placebo group, Dr. Cuzick said that "there’s a general perception that the aromatase inhibitors are very toxic and cause a lot of aches and pains. But 90% of the aches and pains in this study had nothing to do with the drug. They’re just a reflection of the fact that in the postmenopausal years women do get aches and pains."

Vasomotor symptoms occurred in 49% of the placebo group and 57% of women on anastrozole, a statistically significant difference.

Dr. Cuzick said that he believes the sharp reduction in breast cancer seen with anastrozole in IBIS-II is probably a class effect common to the other aromatase inhibitors. In the MAP.3 trial, an earlier study with shorter follow-up (N. Engl. J. Med. 2011;364:2381-91), exemestane showed results similar to those seen in IBIS-II. He added that the greater size and duration of IBIS-II, coupled with the fact that contralateral breast cancer rates continue to be lower at 10 years of follow-up in the anastrozole breast cancer treatment trials, makes him "quite confident" in declaring anastrozole to be the drug of first choice for prevention.

Audience member Dr. Pamela J. Goodwin rose to take issue with that assertion. She noted that there are two approved agents for this indication – tamoxifen and raloxifene – yet placebo was used as the comparator in IBIS-II.

"The evidence is indirect evidence," Dr. Cuzick replied. "Anastrozole and exemestane have shown very, very similar results. The aromatase inhibitors show larger risk reductions than tamoxifen or raloxifene, and overall serious side effects are substantially less. For that reason we think they are the appropriate first choice."

"Those are cross-trial comparisons. I’m not sure I would go that far," retorted Dr. Goodwin, professor of medicine at the University of Toronto.

In a press conference announcing the IBIS-II results, Dr. Cuzick noted that neither tamoxifen nor raloxifene is widely utilized for primary prevention of breast cancer. More public education is in order, he added.

"I think there’s a lot to be done to model what the cardiologists have done: They’ve convinced people that high cholesterol and high blood pressure are actually diseases. In fact, they’re only risk factors, but by taking drugs to reduce those risk factors there’s been a major effect. We need to make people aware there are effective ways of reducing the risk of breast cancer by more than 50%. The toxicities are limited, and if you have toxicity you simply stop treatment," he said.

The IBIS-II study was funded by Cancer Research U.K., the National Health and Medical Research Council of Australia, AstraZeneca, and Sanofi-Aventis. Dr. Cuzick is on the speaker’s bureau for AstraZeneca.

Simultaneous with Dr. Cuzick’s presentation in San Antonio, the IBIS-II results were published online in the Lancet (2013 Dec. 12 [doi:10.1016/S0140-6736(13)62292-8]).

bjancin@frontlinemedcom.com

SAN ANTONIO – The oral tyrosine kinase inhibitor dasatinib appears to increase the efficacy of first-line aromatase inhibitor therapy in women with advanced breast cancer, suggests a randomized phase 2 trial presented at the San Antonio Breast Cancer Symposium.

Adding dasatinib (SPRYCEL) to letrozole (Femara) did not improve the clinical benefit rate – the trial’s primary endpoint – among the 120 postmenopausal women with hormone receptor–positive, HER2-negative locally recurrent or metastatic breast cancer.

But the combination doubled patients’ median progression-free survival from 10 months to 20 months in an intent-to-treat analysis, Dr. Dev Paul of U.S. Oncology and the Rocky Mountain Cancer Centers in Denver reported in a session and a related press briefing at the meeting.

"Dasatinib may be inhibiting the emergence of resistance to aromatase inhibitor therapy," he said.

The researchers were unable to identify factors that explained why the clinical benefit rate was the same, but the progression-free survival was different for the two groups. The study was small, did not use a placebo, and permitted crossover; "all of these things could affect the results, and this is a preliminary exploratory study," Dr. Paul said.

Combining dasatinib with other aromatase inhibitors – fulvestrant or exemestane – has not improved progression-free survival benefit in women with metastatic breast cancer previously treated with a nonsteroidal aromatase inhibitor, Dr. Paul noted; thus, it may be important to give dasatinib the first time that patients are given an aromatase inhibitor. "Putative predictive biomarkers for benefit from dasatinib will be assessed in patients’ archival breast cancer tissues to help inform patient selection for future studies."

In additional findings from the trial, adding dasatinib appeared to attenuate the adverse impact of letrozole on bone health. At the end of the study, patients given the combination therapy were half as likely as their counterparts given letrozole alone to have osteopenia.

The findings on bone density suggest "an on-target effect of the Src inhibitor [dasatinib]," commented Dr. Carlos L. Arteaga, who moderated the press briefing. Dr. Arteaga is president-elect of the American Association for Cancer Research and associate director for translational/clinical research and director of the breast cancer program at Vanderbilt-Ingram Cancer Center in Nashville, Tenn., and a codirector of SABCS.

Dr. Paul noted that the observations occurred in an intent-to-treat analysis that included all patients according to their initial treatment assignment.

During a discussion after the presentation, one session attendee questioned the interpretation that dasatinib was inhibiting the emergence of resistance to letrozole and pointed out that 23% of patients who had progression on letrozole monotherapy had clinical benefit after crossing over to the combination. "You could also interpret the crossover data [as saying] that [dasatinib] simply treats endocrine resistance. So my question is, have you looked at the time to total progression? Have you looked at that 23% clinical benefit in the cross-over group? Because [dasatinib] may not stop resistance, it may just treat it."

Looking at the total time to progression for sequential vs. combined therapy, it may be that the time to progression curves really don’t separate quite so much, the discussant maintained.

Dr. Paul acknowledged that this alternate interpretation was possible and said that such analyses have not yet been done.

"Src is a pleiotropic nonreceptor tyrosine kinase involved in breast cancer invasion, proliferation, and survival. Membrane estrogen receptor-alpha complexes with Src and PI3 kinase to drive breast cancer growth and endocrine therapy resistance," Dr. Paul said, giving some background to the trial. "Src also regulates osteoclast-mediated bone turnover."

Dasatinib inhibits Src tyrosine kinase and is currently approved by the Food and Drug Administration for treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia and chronic myelogenous leukemia.

Women enrolled in the trial were allowed to have had prior non–aromatase inhibitor endocrine therapy for metastatic disease; prior adjuvant aromatase inhibitor therapy if completed at least 1 year before study entry; and one prior chemotherapy regimen for metastatic disease.

After stratification by disease-free interval and prior receipt of tamoxifen, patients were randomized to receive letrozole plus dasatinib or letrozole alone on 28-day cycles.

Patients on letrozole alone were allowed to cross over if they experienced progression, and 56% ultimately did so, Dr. Paul reported.

About half of the women in each treatment arm had not received any prior chemotherapy; 60% of those randomized to the combination and 49% of those randomized to letrozole alone had not received any prior endocrine therapy.

The clinical benefit rate – consisting of complete responses, partial responses, and stable disease for at least 6 months – was 71% with dasatinib plus letrozole and 66% with letrozole alone, a nonsignificant difference.

However, in intent-to-treat analyses, median progression-free survival was more than twice as long with the combination (20.1 months vs. 9.9 months; exploratory hazard ratio, 0.69).

In each treatment arm, about one-third of patients had a bone density T score below –1.5 at baseline, and about one-third received bisphosphonates during the study. But, by the end of the study, the proportion of patients with a T score below –1.5 was smaller in those on combination therapy (14% vs. 32%).

"There were no unexpected toxicities associated with dasatinib," Dr. Paul commented. The addition of this agent was associated with higher rates of grade 3 rash, edema, fatigue, anemia, neutropenia, arthralgia, and pleural effusion, but there were no grade 4 toxicities. Overall, one-quarter of patients needed a dasatinib dose reduction.

Dr. Paul disclosed no relevant conflicts of interest. The trial was sponsored by Bristol-Myers Squibb, the makers of SPRYCEL (dasatinib).

SAN ANTONIO – The oral tyrosine kinase inhibitor dasatinib appears to increase the efficacy of first-line aromatase inhibitor therapy in women with advanced breast cancer, suggests a randomized phase 2 trial presented at the San Antonio Breast Cancer Symposium.

Adding dasatinib (SPRYCEL) to letrozole (Femara) did not improve the clinical benefit rate – the trial’s primary endpoint – among the 120 postmenopausal women with hormone receptor–positive, HER2-negative locally recurrent or metastatic breast cancer.

But the combination doubled patients’ median progression-free survival from 10 months to 20 months in an intent-to-treat analysis, Dr. Dev Paul of U.S. Oncology and the Rocky Mountain Cancer Centers in Denver reported in a session and a related press briefing at the meeting.

"Dasatinib may be inhibiting the emergence of resistance to aromatase inhibitor therapy," he said.

The researchers were unable to identify factors that explained why the clinical benefit rate was the same, but the progression-free survival was different for the two groups. The study was small, did not use a placebo, and permitted crossover; "all of these things could affect the results, and this is a preliminary exploratory study," Dr. Paul said.

Combining dasatinib with other aromatase inhibitors – fulvestrant or exemestane – has not improved progression-free survival benefit in women with metastatic breast cancer previously treated with a nonsteroidal aromatase inhibitor, Dr. Paul noted; thus, it may be important to give dasatinib the first time that patients are given an aromatase inhibitor. "Putative predictive biomarkers for benefit from dasatinib will be assessed in patients’ archival breast cancer tissues to help inform patient selection for future studies."

In additional findings from the trial, adding dasatinib appeared to attenuate the adverse impact of letrozole on bone health. At the end of the study, patients given the combination therapy were half as likely as their counterparts given letrozole alone to have osteopenia.

The findings on bone density suggest "an on-target effect of the Src inhibitor [dasatinib]," commented Dr. Carlos L. Arteaga, who moderated the press briefing. Dr. Arteaga is president-elect of the American Association for Cancer Research and associate director for translational/clinical research and director of the breast cancer program at Vanderbilt-Ingram Cancer Center in Nashville, Tenn., and a codirector of SABCS.

Dr. Paul noted that the observations occurred in an intent-to-treat analysis that included all patients according to their initial treatment assignment.

During a discussion after the presentation, one session attendee questioned the interpretation that dasatinib was inhibiting the emergence of resistance to letrozole and pointed out that 23% of patients who had progression on letrozole monotherapy had clinical benefit after crossing over to the combination. "You could also interpret the crossover data [as saying] that [dasatinib] simply treats endocrine resistance. So my question is, have you looked at the time to total progression? Have you looked at that 23% clinical benefit in the cross-over group? Because [dasatinib] may not stop resistance, it may just treat it."

Looking at the total time to progression for sequential vs. combined therapy, it may be that the time to progression curves really don’t separate quite so much, the discussant maintained.

Dr. Paul acknowledged that this alternate interpretation was possible and said that such analyses have not yet been done.

"Src is a pleiotropic nonreceptor tyrosine kinase involved in breast cancer invasion, proliferation, and survival. Membrane estrogen receptor-alpha complexes with Src and PI3 kinase to drive breast cancer growth and endocrine therapy resistance," Dr. Paul said, giving some background to the trial. "Src also regulates osteoclast-mediated bone turnover."

Dasatinib inhibits Src tyrosine kinase and is currently approved by the Food and Drug Administration for treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia and chronic myelogenous leukemia.

Women enrolled in the trial were allowed to have had prior non–aromatase inhibitor endocrine therapy for metastatic disease; prior adjuvant aromatase inhibitor therapy if completed at least 1 year before study entry; and one prior chemotherapy regimen for metastatic disease.

After stratification by disease-free interval and prior receipt of tamoxifen, patients were randomized to receive letrozole plus dasatinib or letrozole alone on 28-day cycles.

Patients on letrozole alone were allowed to cross over if they experienced progression, and 56% ultimately did so, Dr. Paul reported.

About half of the women in each treatment arm had not received any prior chemotherapy; 60% of those randomized to the combination and 49% of those randomized to letrozole alone had not received any prior endocrine therapy.

The clinical benefit rate – consisting of complete responses, partial responses, and stable disease for at least 6 months – was 71% with dasatinib plus letrozole and 66% with letrozole alone, a nonsignificant difference.

However, in intent-to-treat analyses, median progression-free survival was more than twice as long with the combination (20.1 months vs. 9.9 months; exploratory hazard ratio, 0.69).

In each treatment arm, about one-third of patients had a bone density T score below –1.5 at baseline, and about one-third received bisphosphonates during the study. But, by the end of the study, the proportion of patients with a T score below –1.5 was smaller in those on combination therapy (14% vs. 32%).

"There were no unexpected toxicities associated with dasatinib," Dr. Paul commented. The addition of this agent was associated with higher rates of grade 3 rash, edema, fatigue, anemia, neutropenia, arthralgia, and pleural effusion, but there were no grade 4 toxicities. Overall, one-quarter of patients needed a dasatinib dose reduction.

Dr. Paul disclosed no relevant conflicts of interest. The trial was sponsored by Bristol-Myers Squibb, the makers of SPRYCEL (dasatinib).

SAN ANTONIO – The oral tyrosine kinase inhibitor dasatinib appears to increase the efficacy of first-line aromatase inhibitor therapy in women with advanced breast cancer, suggests a randomized phase 2 trial presented at the San Antonio Breast Cancer Symposium.

Adding dasatinib (SPRYCEL) to letrozole (Femara) did not improve the clinical benefit rate – the trial’s primary endpoint – among the 120 postmenopausal women with hormone receptor–positive, HER2-negative locally recurrent or metastatic breast cancer.

But the combination doubled patients’ median progression-free survival from 10 months to 20 months in an intent-to-treat analysis, Dr. Dev Paul of U.S. Oncology and the Rocky Mountain Cancer Centers in Denver reported in a session and a related press briefing at the meeting.

"Dasatinib may be inhibiting the emergence of resistance to aromatase inhibitor therapy," he said.

The researchers were unable to identify factors that explained why the clinical benefit rate was the same, but the progression-free survival was different for the two groups. The study was small, did not use a placebo, and permitted crossover; "all of these things could affect the results, and this is a preliminary exploratory study," Dr. Paul said.

Combining dasatinib with other aromatase inhibitors – fulvestrant or exemestane – has not improved progression-free survival benefit in women with metastatic breast cancer previously treated with a nonsteroidal aromatase inhibitor, Dr. Paul noted; thus, it may be important to give dasatinib the first time that patients are given an aromatase inhibitor. "Putative predictive biomarkers for benefit from dasatinib will be assessed in patients’ archival breast cancer tissues to help inform patient selection for future studies."

In additional findings from the trial, adding dasatinib appeared to attenuate the adverse impact of letrozole on bone health. At the end of the study, patients given the combination therapy were half as likely as their counterparts given letrozole alone to have osteopenia.

The findings on bone density suggest "an on-target effect of the Src inhibitor [dasatinib]," commented Dr. Carlos L. Arteaga, who moderated the press briefing. Dr. Arteaga is president-elect of the American Association for Cancer Research and associate director for translational/clinical research and director of the breast cancer program at Vanderbilt-Ingram Cancer Center in Nashville, Tenn., and a codirector of SABCS.

Dr. Paul noted that the observations occurred in an intent-to-treat analysis that included all patients according to their initial treatment assignment.

During a discussion after the presentation, one session attendee questioned the interpretation that dasatinib was inhibiting the emergence of resistance to letrozole and pointed out that 23% of patients who had progression on letrozole monotherapy had clinical benefit after crossing over to the combination. "You could also interpret the crossover data [as saying] that [dasatinib] simply treats endocrine resistance. So my question is, have you looked at the time to total progression? Have you looked at that 23% clinical benefit in the cross-over group? Because [dasatinib] may not stop resistance, it may just treat it."

Looking at the total time to progression for sequential vs. combined therapy, it may be that the time to progression curves really don’t separate quite so much, the discussant maintained.

Dr. Paul acknowledged that this alternate interpretation was possible and said that such analyses have not yet been done.

"Src is a pleiotropic nonreceptor tyrosine kinase involved in breast cancer invasion, proliferation, and survival. Membrane estrogen receptor-alpha complexes with Src and PI3 kinase to drive breast cancer growth and endocrine therapy resistance," Dr. Paul said, giving some background to the trial. "Src also regulates osteoclast-mediated bone turnover."

Dasatinib inhibits Src tyrosine kinase and is currently approved by the Food and Drug Administration for treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia and chronic myelogenous leukemia.

Women enrolled in the trial were allowed to have had prior non–aromatase inhibitor endocrine therapy for metastatic disease; prior adjuvant aromatase inhibitor therapy if completed at least 1 year before study entry; and one prior chemotherapy regimen for metastatic disease.

After stratification by disease-free interval and prior receipt of tamoxifen, patients were randomized to receive letrozole plus dasatinib or letrozole alone on 28-day cycles.

Patients on letrozole alone were allowed to cross over if they experienced progression, and 56% ultimately did so, Dr. Paul reported.

About half of the women in each treatment arm had not received any prior chemotherapy; 60% of those randomized to the combination and 49% of those randomized to letrozole alone had not received any prior endocrine therapy.

The clinical benefit rate – consisting of complete responses, partial responses, and stable disease for at least 6 months – was 71% with dasatinib plus letrozole and 66% with letrozole alone, a nonsignificant difference.

However, in intent-to-treat analyses, median progression-free survival was more than twice as long with the combination (20.1 months vs. 9.9 months; exploratory hazard ratio, 0.69).

In each treatment arm, about one-third of patients had a bone density T score below –1.5 at baseline, and about one-third received bisphosphonates during the study. But, by the end of the study, the proportion of patients with a T score below –1.5 was smaller in those on combination therapy (14% vs. 32%).

"There were no unexpected toxicities associated with dasatinib," Dr. Paul commented. The addition of this agent was associated with higher rates of grade 3 rash, edema, fatigue, anemia, neutropenia, arthralgia, and pleural effusion, but there were no grade 4 toxicities. Overall, one-quarter of patients needed a dasatinib dose reduction.

Dr. Paul disclosed no relevant conflicts of interest. The trial was sponsored by Bristol-Myers Squibb, the makers of SPRYCEL (dasatinib).

SAN ANTONIO – High levels of tumor-infiltrating lymphocytes in primary breast cancer are a good biomarker for favorable clinical response to trastuzumab, according to research presented at the San Antonio Breast Cancer Symposium.

In an exclusive interview with Frontline Medical News, Dr. Sherene Loi discusses the findings' clinical implications, including the potential that breast cancers could be amenable to immunotherapeutic approaches.

SAN ANTONIO – High levels of tumor-infiltrating lymphocytes in primary breast cancer are a good biomarker for favorable clinical response to trastuzumab, according to research presented at the San Antonio Breast Cancer Symposium.

In an exclusive interview with Frontline Medical News, Dr. Sherene Loi discusses the findings' clinical implications, including the potential that breast cancers could be amenable to immunotherapeutic approaches.

SAN ANTONIO – High levels of tumor-infiltrating lymphocytes in primary breast cancer are a good biomarker for favorable clinical response to trastuzumab, according to research presented at the San Antonio Breast Cancer Symposium.

In an exclusive interview with Frontline Medical News, Dr. Sherene Loi discusses the findings' clinical implications, including the potential that breast cancers could be amenable to immunotherapeutic approaches.

SAN ANTONIO – Avoiding whole-breast radiation therapy is a reasonable – and even attractive – option for many older women with early-stage breast cancer, according to the results of the Postoperative Radiotherapy in Minimum-Risk Elderly (PRIME II) trial.

The patient population identified in PRIME II as being suitable for omission of postoperative radiotherapy on the basis of a relatively benign natural history consists of women aged 65 or older who are on adjuvant hormone therapy after undergoing lumpectomy with clear margins for estrogen receptor–rich, axillary node–negative breast cancer.

PRIME II was a six-country trial in which 1,326 patients 65 or older with hormone receptor–positive early breast cancer were randomized to radiotherapy or no radiotherapy following breast-conserving surgery and endocrine therapy. The 5-year actuarial rate of ipsilateral breast cancer recurrence – the primary study endpoint – was 1.3% in those who received radiotherapy and 4.1% in those who did not, Dr. Ian H. Kunkler reported at the San Antonio Breast Cancer Symposium.

The 5-year actuarial rate of overall survival was 94.2% in patients randomized to radiotherapy and closely similar at 93.8% in the no-radiotherapy group, added Dr. Kunkler, professor of clinical oncology at the University of Edinburgh.

The relative benefit of radiotherapy was even smaller in the 91% of subjects who had estrogen-rich tumors as defined by an ER score of at least 7. They had a local recurrence rate of 3.2% with radiotherapy and 0.8% without. While that absolute 2.4% difference was statistically significant, it is arguably not clinically meaningful. For every 100 women who fit the description carefully defined in PRIME II and who undergo radiotherapy, three will have a recurrence prevented, one will have a recurrence anyway, and 96 will have had treatment that was not beneficial, he said.

"I think we’re really at the cusp of overtreatment here. I think it’s a matter for discussion between the physician and patient as to whether that very modest benefit is worth the potential complications of radiotherapy and the burdens of ongoing treatment, as well as the costs to the health service. Older patients find radiotherapy very burdensome, the relative benefits are very small, and there is no compromise in terms of overall survival with its omission," Dr. Kunkler said.

An important caveat: Among the 9% of patients with low estrogen receptor status, the local recurrence rate was 11.1% with no radiotherapy compared to zero with radiation.

"This is a group for whom radiotherapy should not be omitted," Dr. Kunkler declared.

More than one-half of all early breast cancers present in women aged 65 or older. While postoperative radiotherapy after lumpectomy has been the standard of care regardless of age and other risk factors, there has been only sparse high-quality supporting evidence for this practice in older patients.

Dr. Kunkler estimated that the PRIME II findings are generalizable to 60%-70% of all breast cancer patients over age 65. He predicted that the PRIME II study will "very likely" alter practice in the United Kingdom, and symposium codirector Dr. C. Kent Osborne predicted that the study will be practice changing in the United States as well.

"When I was in training, everybody thought that more was better: more drug treatment, more radiation, more surgery, high-dose chemotherapy, and bone marrow transplant. As we’ve evolved over the last 3 decades, that’s turning out not to be the case. I think we’re gradually doing less and less treatment, either with radiotherapy or with surgery, to control the local disease in appropriate patients. And I think more and more people will begin to accept it," said Dr. Osborne, director of the Dan L. Duncan Cancer Center and the Lester and Sue Smith Breast Center at Baylor College of Medicine, Houston.

PRIME II was funded by the Chief Scientist Office for Scotland. Dr. Kunkler declared having no conflicts of interest.

bjancin@frontlinemedcom.com

SAN ANTONIO – Avoiding whole-breast radiation therapy is a reasonable – and even attractive – option for many older women with early-stage breast cancer, according to the results of the Postoperative Radiotherapy in Minimum-Risk Elderly (PRIME II) trial.

The patient population identified in PRIME II as being suitable for omission of postoperative radiotherapy on the basis of a relatively benign natural history consists of women aged 65 or older who are on adjuvant hormone therapy after undergoing lumpectomy with clear margins for estrogen receptor–rich, axillary node–negative breast cancer.

PRIME II was a six-country trial in which 1,326 patients 65 or older with hormone receptor–positive early breast cancer were randomized to radiotherapy or no radiotherapy following breast-conserving surgery and endocrine therapy. The 5-year actuarial rate of ipsilateral breast cancer recurrence – the primary study endpoint – was 1.3% in those who received radiotherapy and 4.1% in those who did not, Dr. Ian H. Kunkler reported at the San Antonio Breast Cancer Symposium.

The 5-year actuarial rate of overall survival was 94.2% in patients randomized to radiotherapy and closely similar at 93.8% in the no-radiotherapy group, added Dr. Kunkler, professor of clinical oncology at the University of Edinburgh.

The relative benefit of radiotherapy was even smaller in the 91% of subjects who had estrogen-rich tumors as defined by an ER score of at least 7. They had a local recurrence rate of 3.2% with radiotherapy and 0.8% without. While that absolute 2.4% difference was statistically significant, it is arguably not clinically meaningful. For every 100 women who fit the description carefully defined in PRIME II and who undergo radiotherapy, three will have a recurrence prevented, one will have a recurrence anyway, and 96 will have had treatment that was not beneficial, he said.

"I think we’re really at the cusp of overtreatment here. I think it’s a matter for discussion between the physician and patient as to whether that very modest benefit is worth the potential complications of radiotherapy and the burdens of ongoing treatment, as well as the costs to the health service. Older patients find radiotherapy very burdensome, the relative benefits are very small, and there is no compromise in terms of overall survival with its omission," Dr. Kunkler said.

An important caveat: Among the 9% of patients with low estrogen receptor status, the local recurrence rate was 11.1% with no radiotherapy compared to zero with radiation.

"This is a group for whom radiotherapy should not be omitted," Dr. Kunkler declared.

More than one-half of all early breast cancers present in women aged 65 or older. While postoperative radiotherapy after lumpectomy has been the standard of care regardless of age and other risk factors, there has been only sparse high-quality supporting evidence for this practice in older patients.

Dr. Kunkler estimated that the PRIME II findings are generalizable to 60%-70% of all breast cancer patients over age 65. He predicted that the PRIME II study will "very likely" alter practice in the United Kingdom, and symposium codirector Dr. C. Kent Osborne predicted that the study will be practice changing in the United States as well.

"When I was in training, everybody thought that more was better: more drug treatment, more radiation, more surgery, high-dose chemotherapy, and bone marrow transplant. As we’ve evolved over the last 3 decades, that’s turning out not to be the case. I think we’re gradually doing less and less treatment, either with radiotherapy or with surgery, to control the local disease in appropriate patients. And I think more and more people will begin to accept it," said Dr. Osborne, director of the Dan L. Duncan Cancer Center and the Lester and Sue Smith Breast Center at Baylor College of Medicine, Houston.

PRIME II was funded by the Chief Scientist Office for Scotland. Dr. Kunkler declared having no conflicts of interest.

bjancin@frontlinemedcom.com

SAN ANTONIO – Avoiding whole-breast radiation therapy is a reasonable – and even attractive – option for many older women with early-stage breast cancer, according to the results of the Postoperative Radiotherapy in Minimum-Risk Elderly (PRIME II) trial.

The patient population identified in PRIME II as being suitable for omission of postoperative radiotherapy on the basis of a relatively benign natural history consists of women aged 65 or older who are on adjuvant hormone therapy after undergoing lumpectomy with clear margins for estrogen receptor–rich, axillary node–negative breast cancer.

PRIME II was a six-country trial in which 1,326 patients 65 or older with hormone receptor–positive early breast cancer were randomized to radiotherapy or no radiotherapy following breast-conserving surgery and endocrine therapy. The 5-year actuarial rate of ipsilateral breast cancer recurrence – the primary study endpoint – was 1.3% in those who received radiotherapy and 4.1% in those who did not, Dr. Ian H. Kunkler reported at the San Antonio Breast Cancer Symposium.

The 5-year actuarial rate of overall survival was 94.2% in patients randomized to radiotherapy and closely similar at 93.8% in the no-radiotherapy group, added Dr. Kunkler, professor of clinical oncology at the University of Edinburgh.

The relative benefit of radiotherapy was even smaller in the 91% of subjects who had estrogen-rich tumors as defined by an ER score of at least 7. They had a local recurrence rate of 3.2% with radiotherapy and 0.8% without. While that absolute 2.4% difference was statistically significant, it is arguably not clinically meaningful. For every 100 women who fit the description carefully defined in PRIME II and who undergo radiotherapy, three will have a recurrence prevented, one will have a recurrence anyway, and 96 will have had treatment that was not beneficial, he said.

"I think we’re really at the cusp of overtreatment here. I think it’s a matter for discussion between the physician and patient as to whether that very modest benefit is worth the potential complications of radiotherapy and the burdens of ongoing treatment, as well as the costs to the health service. Older patients find radiotherapy very burdensome, the relative benefits are very small, and there is no compromise in terms of overall survival with its omission," Dr. Kunkler said.

An important caveat: Among the 9% of patients with low estrogen receptor status, the local recurrence rate was 11.1% with no radiotherapy compared to zero with radiation.

"This is a group for whom radiotherapy should not be omitted," Dr. Kunkler declared.

More than one-half of all early breast cancers present in women aged 65 or older. While postoperative radiotherapy after lumpectomy has been the standard of care regardless of age and other risk factors, there has been only sparse high-quality supporting evidence for this practice in older patients.

Dr. Kunkler estimated that the PRIME II findings are generalizable to 60%-70% of all breast cancer patients over age 65. He predicted that the PRIME II study will "very likely" alter practice in the United Kingdom, and symposium codirector Dr. C. Kent Osborne predicted that the study will be practice changing in the United States as well.

"When I was in training, everybody thought that more was better: more drug treatment, more radiation, more surgery, high-dose chemotherapy, and bone marrow transplant. As we’ve evolved over the last 3 decades, that’s turning out not to be the case. I think we’re gradually doing less and less treatment, either with radiotherapy or with surgery, to control the local disease in appropriate patients. And I think more and more people will begin to accept it," said Dr. Osborne, director of the Dan L. Duncan Cancer Center and the Lester and Sue Smith Breast Center at Baylor College of Medicine, Houston.

PRIME II was funded by the Chief Scientist Office for Scotland. Dr. Kunkler declared having no conflicts of interest.

bjancin@frontlinemedcom.com

SAN ANTONIO – Pathologic complete response is a strong prognostic factor in women with HER2-positive early breast cancer who receive neoadjuvant HER2-targeted therapy, investigators reported at the annual San Antonio Breast Cancer Symposium.

A team led by Dr. Martine Piccart-Gebhart, chair of the Breast International Group (BIG) in Brussels, analyzed data from 455 patients in the randomized NeoALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) trial, who received one or both HER2 therapies, along with chemotherapy.

With a median follow-up of almost 4 years, those who experienced a pathologic complete response (pCR) – meaning no detectable invasive disease in either the breast or axilla at surgery – were 62% less likely to have had events such as recurrences or second primaries, and 65% less likely to have died, she reported in a session and related press briefing.

The benefit of pCR was more pronounced among patients whose tumors were negative for hormone receptors than among their counterparts whose tumors were positive.

The new data should not change the standard of care, trastuzumab and chemotherapy, she cautioned. "But what this trial indicates to us is that it is possible that for this particular subgroup – hormone receptor–negative, HER2-positive – we could potentially use a neoadjuvant model to speed up approval of new agents. And that’s important because we know that adjuvant trials in breast cancer take forever and are very time- and money-consuming, and require thousands of patients."

Thus, the findings would lend support to the Food and Drug Administration’s use of pCR as the bar for accelerated approval of new drugs for this patient subgroup, she said.

Event-free and overall survival did not differ significantly according to the specific HER2 therapy received, although dual therapy tended to have an edge in patients with hormone receptor–negative tumors. However, the trial was not powered to detect moderate differences in these outcomes, according to Dr. Piccart-Gebhart.

"It is the very large ALTTO trial, with the recruitment of 8,300 women, that will provide a robust answer on the effect of dual HER2 blockade on long-term outcomes, and we expect to report these results at ASCO [American Society of Clinical Oncology] next year," she commented.

Analyses of NeoALTTO will be repeated after another 2.5 years, Dr. Piccart-Gebhart added. "It is possible that with longer follow-up, we will also see a bigger treatment effect in the hormone receptor–positive subgroup. But clearly, this trial provides further evidence that HER2-positive, hormone receptor–negative and HER2-positive, hormone receptor–positive groups are two different diseases."

Press briefing moderator Dr. Jennifer Litton of the department of breast medical oncology at the University of Texas MD Anderson Cancer Center, Houston, noted that pCR was used to gain initial approval of pertuzumab (Perjeta), another targeted therapy, in the neoadjuvant setting.

The reported data "in my opinion, show that it continues to be a very valid surrogate endpoint, and continues to [address the issue] of how we can develop new drugs, get them to patients quicker, with a smaller number of patients involved and less cost," she said.

Session attendee Dr. Steven E. Vogl, an oncologist in New York, asked whether pCR should be abandoned as a surrogate marker for the hormone receptor–positive subset. "It looks like the benefit of pCR was, at best, tiny in your study for those women, and probably we should think twice about using pCR in deciding which therapy is better – we should wait for event-free and overall survival. What do you think?"

Dr. Piccart-Gebhart replied that a meta-analysis of HER2 neoadjuvant therapy performed by the FDA with a much longer follow-up did find a benefit of pCR in the hormone receptor–positive subset. "It was less striking, but it was there. So I think that we have to be cautious because NeoALTTO is still a relatively small study.

"But I would tend to agree with you that the data look a lot stronger in the hormone receptor–negative subgroup, and there, based on the results I showed today, I feel confident that you could use the neoadjuvant model for accelerated approval of new drugs," she added. "For the hormone receptor–positive patients, I’m a little bit more cautious. I think these are slow actors. The events come later; you need a longer follow-up. And then of course the endocrine treatment is important and you give it after surgery in all these trials, which could be a mistake."

In the NeoALTTO study (also known as BIG 1-06), women with HER2-positive early breast cancer measuring at least 2 cm were randomly assigned to 18 weeks of neoadjuvant therapy with dual HER2 blockade using both lapatinib (Tykerb) and trastuzumab (Herceptin), or single HER2 blockade with one of the agents alone – each given along with paclitaxel.

After surgery, they received combination chemotherapy and then more of the same HER2 therapy out to 52 weeks, as well as hormonal therapy if indicated.

Initial results, previously reported, showed that the rate of pCR – the trial’s primary endpoint – was 24.7% with lapatinib alone, 29.5% with trastuzumab alone, and 51.3% with the combination, Dr. Piccart-Gebhart reported.

The new results showed that there were no significant differences between the treatment arms in the adjusted 3-year rates of event-free survival (78%, 76%, and 84%, respectively) or overall survival (93%, 90%, and 95%, respectively). But there was greater separation of the curves in the hormone receptor–negative subset, suggesting a possible treatment effect, according to Dr. Piccart-Gebhart.

In an analysis of all trial arms combined that used a starting point of 30 weeks after randomization, relative to patients who did not have a pCR, those who did were significantly less likely to have events (postoperative recurrence, second primary, or death, or progression in those who did not have surgery) (hazard ratio, 0.38; P = .0003) and to die (HR, 0.35; P = .005).

"There were no surprises" in terms of adverse events, she reported. "The adverse events were consistent with the known safety profiles of lapatinib and trastuzumab."

Over the entire study period, compared with trastuzumab alone, the combination of lapatinib plus trastuzumab led to higher rates of severe diarrhea, hepatobiliary adverse events, and rash, as well as a higher rate of cardiac events.

Dr. Piccart-Gebhart disclosed that she has received consulting fees from Roche, and her institution has received research funding from GlaxoSmithKline PLC and Roche. The trial was sponsored by GlaxoSmithKline.

SAN ANTONIO – Pathologic complete response is a strong prognostic factor in women with HER2-positive early breast cancer who receive neoadjuvant HER2-targeted therapy, investigators reported at the annual San Antonio Breast Cancer Symposium.

A team led by Dr. Martine Piccart-Gebhart, chair of the Breast International Group (BIG) in Brussels, analyzed data from 455 patients in the randomized NeoALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) trial, who received one or both HER2 therapies, along with chemotherapy.

With a median follow-up of almost 4 years, those who experienced a pathologic complete response (pCR) – meaning no detectable invasive disease in either the breast or axilla at surgery – were 62% less likely to have had events such as recurrences or second primaries, and 65% less likely to have died, she reported in a session and related press briefing.

The benefit of pCR was more pronounced among patients whose tumors were negative for hormone receptors than among their counterparts whose tumors were positive.

The new data should not change the standard of care, trastuzumab and chemotherapy, she cautioned. "But what this trial indicates to us is that it is possible that for this particular subgroup – hormone receptor–negative, HER2-positive – we could potentially use a neoadjuvant model to speed up approval of new agents. And that’s important because we know that adjuvant trials in breast cancer take forever and are very time- and money-consuming, and require thousands of patients."

Thus, the findings would lend support to the Food and Drug Administration’s use of pCR as the bar for accelerated approval of new drugs for this patient subgroup, she said.

Event-free and overall survival did not differ significantly according to the specific HER2 therapy received, although dual therapy tended to have an edge in patients with hormone receptor–negative tumors. However, the trial was not powered to detect moderate differences in these outcomes, according to Dr. Piccart-Gebhart.

"It is the very large ALTTO trial, with the recruitment of 8,300 women, that will provide a robust answer on the effect of dual HER2 blockade on long-term outcomes, and we expect to report these results at ASCO [American Society of Clinical Oncology] next year," she commented.

Analyses of NeoALTTO will be repeated after another 2.5 years, Dr. Piccart-Gebhart added. "It is possible that with longer follow-up, we will also see a bigger treatment effect in the hormone receptor–positive subgroup. But clearly, this trial provides further evidence that HER2-positive, hormone receptor–negative and HER2-positive, hormone receptor–positive groups are two different diseases."

Press briefing moderator Dr. Jennifer Litton of the department of breast medical oncology at the University of Texas MD Anderson Cancer Center, Houston, noted that pCR was used to gain initial approval of pertuzumab (Perjeta), another targeted therapy, in the neoadjuvant setting.

The reported data "in my opinion, show that it continues to be a very valid surrogate endpoint, and continues to [address the issue] of how we can develop new drugs, get them to patients quicker, with a smaller number of patients involved and less cost," she said.

Session attendee Dr. Steven E. Vogl, an oncologist in New York, asked whether pCR should be abandoned as a surrogate marker for the hormone receptor–positive subset. "It looks like the benefit of pCR was, at best, tiny in your study for those women, and probably we should think twice about using pCR in deciding which therapy is better – we should wait for event-free and overall survival. What do you think?"

Dr. Piccart-Gebhart replied that a meta-analysis of HER2 neoadjuvant therapy performed by the FDA with a much longer follow-up did find a benefit of pCR in the hormone receptor–positive subset. "It was less striking, but it was there. So I think that we have to be cautious because NeoALTTO is still a relatively small study.

"But I would tend to agree with you that the data look a lot stronger in the hormone receptor–negative subgroup, and there, based on the results I showed today, I feel confident that you could use the neoadjuvant model for accelerated approval of new drugs," she added. "For the hormone receptor–positive patients, I’m a little bit more cautious. I think these are slow actors. The events come later; you need a longer follow-up. And then of course the endocrine treatment is important and you give it after surgery in all these trials, which could be a mistake."

In the NeoALTTO study (also known as BIG 1-06), women with HER2-positive early breast cancer measuring at least 2 cm were randomly assigned to 18 weeks of neoadjuvant therapy with dual HER2 blockade using both lapatinib (Tykerb) and trastuzumab (Herceptin), or single HER2 blockade with one of the agents alone – each given along with paclitaxel.

After surgery, they received combination chemotherapy and then more of the same HER2 therapy out to 52 weeks, as well as hormonal therapy if indicated.

Initial results, previously reported, showed that the rate of pCR – the trial’s primary endpoint – was 24.7% with lapatinib alone, 29.5% with trastuzumab alone, and 51.3% with the combination, Dr. Piccart-Gebhart reported.

The new results showed that there were no significant differences between the treatment arms in the adjusted 3-year rates of event-free survival (78%, 76%, and 84%, respectively) or overall survival (93%, 90%, and 95%, respectively). But there was greater separation of the curves in the hormone receptor–negative subset, suggesting a possible treatment effect, according to Dr. Piccart-Gebhart.

In an analysis of all trial arms combined that used a starting point of 30 weeks after randomization, relative to patients who did not have a pCR, those who did were significantly less likely to have events (postoperative recurrence, second primary, or death, or progression in those who did not have surgery) (hazard ratio, 0.38; P = .0003) and to die (HR, 0.35; P = .005).

"There were no surprises" in terms of adverse events, she reported. "The adverse events were consistent with the known safety profiles of lapatinib and trastuzumab."

Over the entire study period, compared with trastuzumab alone, the combination of lapatinib plus trastuzumab led to higher rates of severe diarrhea, hepatobiliary adverse events, and rash, as well as a higher rate of cardiac events.

Dr. Piccart-Gebhart disclosed that she has received consulting fees from Roche, and her institution has received research funding from GlaxoSmithKline PLC and Roche. The trial was sponsored by GlaxoSmithKline.

SAN ANTONIO – Pathologic complete response is a strong prognostic factor in women with HER2-positive early breast cancer who receive neoadjuvant HER2-targeted therapy, investigators reported at the annual San Antonio Breast Cancer Symposium.

A team led by Dr. Martine Piccart-Gebhart, chair of the Breast International Group (BIG) in Brussels, analyzed data from 455 patients in the randomized NeoALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) trial, who received one or both HER2 therapies, along with chemotherapy.

With a median follow-up of almost 4 years, those who experienced a pathologic complete response (pCR) – meaning no detectable invasive disease in either the breast or axilla at surgery – were 62% less likely to have had events such as recurrences or second primaries, and 65% less likely to have died, she reported in a session and related press briefing.

The benefit of pCR was more pronounced among patients whose tumors were negative for hormone receptors than among their counterparts whose tumors were positive.

The new data should not change the standard of care, trastuzumab and chemotherapy, she cautioned. "But what this trial indicates to us is that it is possible that for this particular subgroup – hormone receptor–negative, HER2-positive – we could potentially use a neoadjuvant model to speed up approval of new agents. And that’s important because we know that adjuvant trials in breast cancer take forever and are very time- and money-consuming, and require thousands of patients."

Thus, the findings would lend support to the Food and Drug Administration’s use of pCR as the bar for accelerated approval of new drugs for this patient subgroup, she said.

Event-free and overall survival did not differ significantly according to the specific HER2 therapy received, although dual therapy tended to have an edge in patients with hormone receptor–negative tumors. However, the trial was not powered to detect moderate differences in these outcomes, according to Dr. Piccart-Gebhart.

"It is the very large ALTTO trial, with the recruitment of 8,300 women, that will provide a robust answer on the effect of dual HER2 blockade on long-term outcomes, and we expect to report these results at ASCO [American Society of Clinical Oncology] next year," she commented.

Analyses of NeoALTTO will be repeated after another 2.5 years, Dr. Piccart-Gebhart added. "It is possible that with longer follow-up, we will also see a bigger treatment effect in the hormone receptor–positive subgroup. But clearly, this trial provides further evidence that HER2-positive, hormone receptor–negative and HER2-positive, hormone receptor–positive groups are two different diseases."

Press briefing moderator Dr. Jennifer Litton of the department of breast medical oncology at the University of Texas MD Anderson Cancer Center, Houston, noted that pCR was used to gain initial approval of pertuzumab (Perjeta), another targeted therapy, in the neoadjuvant setting.

The reported data "in my opinion, show that it continues to be a very valid surrogate endpoint, and continues to [address the issue] of how we can develop new drugs, get them to patients quicker, with a smaller number of patients involved and less cost," she said.

Session attendee Dr. Steven E. Vogl, an oncologist in New York, asked whether pCR should be abandoned as a surrogate marker for the hormone receptor–positive subset. "It looks like the benefit of pCR was, at best, tiny in your study for those women, and probably we should think twice about using pCR in deciding which therapy is better – we should wait for event-free and overall survival. What do you think?"

Dr. Piccart-Gebhart replied that a meta-analysis of HER2 neoadjuvant therapy performed by the FDA with a much longer follow-up did find a benefit of pCR in the hormone receptor–positive subset. "It was less striking, but it was there. So I think that we have to be cautious because NeoALTTO is still a relatively small study.

"But I would tend to agree with you that the data look a lot stronger in the hormone receptor–negative subgroup, and there, based on the results I showed today, I feel confident that you could use the neoadjuvant model for accelerated approval of new drugs," she added. "For the hormone receptor–positive patients, I’m a little bit more cautious. I think these are slow actors. The events come later; you need a longer follow-up. And then of course the endocrine treatment is important and you give it after surgery in all these trials, which could be a mistake."

In the NeoALTTO study (also known as BIG 1-06), women with HER2-positive early breast cancer measuring at least 2 cm were randomly assigned to 18 weeks of neoadjuvant therapy with dual HER2 blockade using both lapatinib (Tykerb) and trastuzumab (Herceptin), or single HER2 blockade with one of the agents alone – each given along with paclitaxel.

After surgery, they received combination chemotherapy and then more of the same HER2 therapy out to 52 weeks, as well as hormonal therapy if indicated.

Initial results, previously reported, showed that the rate of pCR – the trial’s primary endpoint – was 24.7% with lapatinib alone, 29.5% with trastuzumab alone, and 51.3% with the combination, Dr. Piccart-Gebhart reported.

The new results showed that there were no significant differences between the treatment arms in the adjusted 3-year rates of event-free survival (78%, 76%, and 84%, respectively) or overall survival (93%, 90%, and 95%, respectively). But there was greater separation of the curves in the hormone receptor–negative subset, suggesting a possible treatment effect, according to Dr. Piccart-Gebhart.

In an analysis of all trial arms combined that used a starting point of 30 weeks after randomization, relative to patients who did not have a pCR, those who did were significantly less likely to have events (postoperative recurrence, second primary, or death, or progression in those who did not have surgery) (hazard ratio, 0.38; P = .0003) and to die (HR, 0.35; P = .005).

"There were no surprises" in terms of adverse events, she reported. "The adverse events were consistent with the known safety profiles of lapatinib and trastuzumab."

Over the entire study period, compared with trastuzumab alone, the combination of lapatinib plus trastuzumab led to higher rates of severe diarrhea, hepatobiliary adverse events, and rash, as well as a higher rate of cardiac events.

Dr. Piccart-Gebhart disclosed that she has received consulting fees from Roche, and her institution has received research funding from GlaxoSmithKline PLC and Roche. The trial was sponsored by GlaxoSmithKline.

SAN ANTONIO – Dr. William J. Gradishar, Betsy Bramsen Professor of Breast Oncology at Northwestern University Feinberg School of Medicine, Chicago; and Dr. Hope S. Rugo, Director, Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, discuss the best to come from the San Antonio Breast Cancer Symposium, including:

• The ECOG, Turkish, and Indian trials that examine whether mastectomy results in better outcomes for the 10% of patients who present with de novo metastatic breast cancer and an intact primary tumor, as well as the accrual status of the U.S. trial examining this issue.

• The parameters of the NeoALTTO trial and the implications of dual targeting in early and preoperative HER2-positive breast cancer.

• Trials aiming to find less toxic regimens, and examining whether and when giving less – such as providing weekly paclitaxel for 12 weeks and a year of trastuzumab – is a better approach.

• Reports from a SWOG trial that will examine whether the numeric levels of circulating tumor cell markers can be used to make changes in therapy for patients with metastatic disease, and whether those changes can improve patients’ overall outcomes.

• Studies on novel agents in the neoadjuvant setting, including the CALGB 40603 trial of paclitaxel with and without bevacizumab and with and without carboplatin in patients with triple-negative disease. The findings may have implications for how newer agents are tested in patients with triple-negative disease.

Dr. Gradishar and Dr. Rugo also discuss reports on one of the arms of the I-SPY2 trial examining adaptive randomization of patients with MammaPrint high-risk disease to standard neoadjuvant chemotherapy vs. novel agents with paclitaxel, followed by anthracycline. The results represent the first oral presentation of data on the PARP inhibitor veliparib and carboplatin.

mdales@frontlinemedcom.com

SAN ANTONIO – Dr. William J. Gradishar, Betsy Bramsen Professor of Breast Oncology at Northwestern University Feinberg School of Medicine, Chicago; and Dr. Hope S. Rugo, Director, Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, discuss the best to come from the San Antonio Breast Cancer Symposium, including:

• The ECOG, Turkish, and Indian trials that examine whether mastectomy results in better outcomes for the 10% of patients who present with de novo metastatic breast cancer and an intact primary tumor, as well as the accrual status of the U.S. trial examining this issue.

• The parameters of the NeoALTTO trial and the implications of dual targeting in early and preoperative HER2-positive breast cancer.

• Trials aiming to find less toxic regimens, and examining whether and when giving less – such as providing weekly paclitaxel for 12 weeks and a year of trastuzumab – is a better approach.

• Reports from a SWOG trial that will examine whether the numeric levels of circulating tumor cell markers can be used to make changes in therapy for patients with metastatic disease, and whether those changes can improve patients’ overall outcomes.

• Studies on novel agents in the neoadjuvant setting, including the CALGB 40603 trial of paclitaxel with and without bevacizumab and with and without carboplatin in patients with triple-negative disease. The findings may have implications for how newer agents are tested in patients with triple-negative disease.

Dr. Gradishar and Dr. Rugo also discuss reports on one of the arms of the I-SPY2 trial examining adaptive randomization of patients with MammaPrint high-risk disease to standard neoadjuvant chemotherapy vs. novel agents with paclitaxel, followed by anthracycline. The results represent the first oral presentation of data on the PARP inhibitor veliparib and carboplatin.

mdales@frontlinemedcom.com

SAN ANTONIO – Dr. William J. Gradishar, Betsy Bramsen Professor of Breast Oncology at Northwestern University Feinberg School of Medicine, Chicago; and Dr. Hope S. Rugo, Director, Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, discuss the best to come from the San Antonio Breast Cancer Symposium, including:

• The ECOG, Turkish, and Indian trials that examine whether mastectomy results in better outcomes for the 10% of patients who present with de novo metastatic breast cancer and an intact primary tumor, as well as the accrual status of the U.S. trial examining this issue.

• The parameters of the NeoALTTO trial and the implications of dual targeting in early and preoperative HER2-positive breast cancer.

• Trials aiming to find less toxic regimens, and examining whether and when giving less – such as providing weekly paclitaxel for 12 weeks and a year of trastuzumab – is a better approach.

• Reports from a SWOG trial that will examine whether the numeric levels of circulating tumor cell markers can be used to make changes in therapy for patients with metastatic disease, and whether those changes can improve patients’ overall outcomes.

• Studies on novel agents in the neoadjuvant setting, including the CALGB 40603 trial of paclitaxel with and without bevacizumab and with and without carboplatin in patients with triple-negative disease. The findings may have implications for how newer agents are tested in patients with triple-negative disease.

Dr. Gradishar and Dr. Rugo also discuss reports on one of the arms of the I-SPY2 trial examining adaptive randomization of patients with MammaPrint high-risk disease to standard neoadjuvant chemotherapy vs. novel agents with paclitaxel, followed by anthracycline. The results represent the first oral presentation of data on the PARP inhibitor veliparib and carboplatin.

mdales@frontlinemedcom.com

A notice about the risk of severe skin reactions associated with the cancer drug capecitabine – including Stevens-Johnson syndrome – has been released by the Canadian health department.

"Very rare cases of severe cutaneous reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), in some cases with fatal outcome, have been reported during treatment with" capecitabine, according to a letter to health care professionals, posted on the Health Canada website on Dec. 3. The letter states that treatment with capecitabine should be "immediately discontinued" if a patient develops signs and symptoms of SJS or TEN.

No such notice has been posted by the U.S. Food and Drug Administration. The FDA "constantly monitors and reviews reports from regulatory agencies, especially those concerning products that affect Americans’ health," and is reviewing related scientific information on this issue, an FDA spokesperson said in response to a query on the notice. The agency "will determine what, if any, actions to take," he added.

Capecitabine is a nucleoside metabolic inhibitor, and is marketed as Xeloda in Canada and the United States for treatment of colorectal cancer and breast cancer. In the United States, it was initially approved in 1998 for treating metastatic breast cancer, and is now also approved as a first-line treatment for metastatic colon cancer, as well as for adjuvant colon cancer in patients with Dukes’ C colon cancer. It is marketed by Roche, which the letter says is working with Health Canada to revise the product monograph in Canada. In the United States, a generic formulation is also available.

The U.S. label includes hand-and-foot syndrome (including grade 2 and 3 events), dermatitis, rash, and erythema among the skin and subcutaneous adverse events reported in clinical trials, but there are no reports of SJS or TEN listed.

Serious adverse events associated with capecitabine should be reported to MedWatch, the FDA Safety Information and Adverse Event Reporting Program, at www.fda.gov/Safety/MedWatch/default.htm.

emechcatie@frontlinemedcom.com

A notice about the risk of severe skin reactions associated with the cancer drug capecitabine – including Stevens-Johnson syndrome – has been released by the Canadian health department.

"Very rare cases of severe cutaneous reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), in some cases with fatal outcome, have been reported during treatment with" capecitabine, according to a letter to health care professionals, posted on the Health Canada website on Dec. 3. The letter states that treatment with capecitabine should be "immediately discontinued" if a patient develops signs and symptoms of SJS or TEN.

No such notice has been posted by the U.S. Food and Drug Administration. The FDA "constantly monitors and reviews reports from regulatory agencies, especially those concerning products that affect Americans’ health," and is reviewing related scientific information on this issue, an FDA spokesperson said in response to a query on the notice. The agency "will determine what, if any, actions to take," he added.

Capecitabine is a nucleoside metabolic inhibitor, and is marketed as Xeloda in Canada and the United States for treatment of colorectal cancer and breast cancer. In the United States, it was initially approved in 1998 for treating metastatic breast cancer, and is now also approved as a first-line treatment for metastatic colon cancer, as well as for adjuvant colon cancer in patients with Dukes’ C colon cancer. It is marketed by Roche, which the letter says is working with Health Canada to revise the product monograph in Canada. In the United States, a generic formulation is also available.

The U.S. label includes hand-and-foot syndrome (including grade 2 and 3 events), dermatitis, rash, and erythema among the skin and subcutaneous adverse events reported in clinical trials, but there are no reports of SJS or TEN listed.

Serious adverse events associated with capecitabine should be reported to MedWatch, the FDA Safety Information and Adverse Event Reporting Program, at www.fda.gov/Safety/MedWatch/default.htm.

emechcatie@frontlinemedcom.com

A notice about the risk of severe skin reactions associated with the cancer drug capecitabine – including Stevens-Johnson syndrome – has been released by the Canadian health department.

"Very rare cases of severe cutaneous reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), in some cases with fatal outcome, have been reported during treatment with" capecitabine, according to a letter to health care professionals, posted on the Health Canada website on Dec. 3. The letter states that treatment with capecitabine should be "immediately discontinued" if a patient develops signs and symptoms of SJS or TEN.

No such notice has been posted by the U.S. Food and Drug Administration. The FDA "constantly monitors and reviews reports from regulatory agencies, especially those concerning products that affect Americans’ health," and is reviewing related scientific information on this issue, an FDA spokesperson said in response to a query on the notice. The agency "will determine what, if any, actions to take," he added.

Capecitabine is a nucleoside metabolic inhibitor, and is marketed as Xeloda in Canada and the United States for treatment of colorectal cancer and breast cancer. In the United States, it was initially approved in 1998 for treating metastatic breast cancer, and is now also approved as a first-line treatment for metastatic colon cancer, as well as for adjuvant colon cancer in patients with Dukes’ C colon cancer. It is marketed by Roche, which the letter says is working with Health Canada to revise the product monograph in Canada. In the United States, a generic formulation is also available.

The U.S. label includes hand-and-foot syndrome (including grade 2 and 3 events), dermatitis, rash, and erythema among the skin and subcutaneous adverse events reported in clinical trials, but there are no reports of SJS or TEN listed.

Serious adverse events associated with capecitabine should be reported to MedWatch, the FDA Safety Information and Adverse Event Reporting Program, at www.fda.gov/Safety/MedWatch/default.htm.

emechcatie@frontlinemedcom.com

CHICAGO – Screening all-comers with three-dimensional mammography increased breast cancer detection by 22.7% and reduced recall rates by 15.6% in a large observational study.

Although a 3D digital breast tomosynthesis (DBT) system was approved for breast cancer screening and diagnosis in the United States in 2011, DBT is typically a supplemental screening tool to standard 2D digital mammography.

In November 2011, however, the Hospital of the University of Pennsylvania, Philadelphia, took the plunge and began using DBT for every breast screening patient, regardless of age, cancer risk, breast density, or ability to pay.

Over a 17-month-period, DBT detected 82 cancers in 15,632 women, or 5.25 cancers per 1,000 cases, Dr. Emily F. Conant reported at the annual meeting of the Radiological Society of North America.

This compares with 46 cancers, or 4.28 cancers per 1,000 cases, detected with conventional mammography in 10,752 women in the 12 months prior to the switch.

The difference in cancer detection rates between 2D and 3D mammography did not reach statistical significance (P = .226), probably because of the small number of cases, Dr. Conant, a radiology professor at the hospital, said at a press briefing.

Compared with conventional mammography, however, DBT significantly improved the proportion of positive screening mammograms from which cancer was diagnosed by 45% (P = .036) and increased the detection of deadly invasive cancers by a nonsignificant 31%.

When asked whether the study showed that invasive lobular cancer can be better detected with DBT, Dr. Conant replied, "Yes. Those were the most remarkable cases, because those tumors tend to be large at presentation and notoriously difficult to detect because they don’t often form the mass that an invasive ductal carcinoma does."

Press briefing moderator Dr. Debra L. Somers Copit, chief of mammography and director of the Gershon-Cohen Breast Clinic at Einstein Medical Center, Philadelphia, described the improvements in cancer detection in the real-world cohort as "groundbreaking work for this modality that we hope will pan out across multiple institutions."

Reimbursement is problematic, however, as insurers will only pay for 2D mammography images taken as part of a tomosynthesis screening exam, she said in an interview.

Still, she personally believes tomosynthesis should now be the standard of care, adding, "I can’t imagine reading a mammogram without it."

Results from the current study are comparable with data reported recently from trials in the United States (Radiology 2013;269:694-700) and Norway (Eur. Radiol. 2013;23:2061-71) that paired 2D imaging with 3D tomosynthesis, Dr. Conant observed.

When the investigators looked at the independent risk factor of breast density, DBT also did a better job of detecting cancer than conventional mammography in fatty, scattered, heterogeneous, and extremely dense breasts, and it improved recall rates for all categories except extremely dense breasts, she said.

Overall, DBT significantly reduced the proportion of women recalled for additional imaging from 10.39% to 8.77% (P = .001).

DBT is an exciting improvement over 2D mammography and more economical than breast screening with magnetic resonance imaging, but it is "not the solution to everything," Dr. Conant said. The radiation dose for the average breast is within safety limits, but twice that of a regular mammogram.

"The cost to the patient is not monetary at our site; it may be at other sites," she said. "I think right now the dose is the biggest cost."

The May 2013 approval of Hologic’s C-View 2D imaging software, which eliminates the need for additional 2D exposures by generating 2D images from 3D tomosynthesis data, might address this, Dr. Conant added.

Dr. Conant reported consulting for Hologic. Her coauthors reported no financial disclosures. Dr. Copit is on Hologic’s scientific advisory board.

pwendling@frontlinemedcom.com

CHICAGO – Screening all-comers with three-dimensional mammography increased breast cancer detection by 22.7% and reduced recall rates by 15.6% in a large observational study.

Although a 3D digital breast tomosynthesis (DBT) system was approved for breast cancer screening and diagnosis in the United States in 2011, DBT is typically a supplemental screening tool to standard 2D digital mammography.

In November 2011, however, the Hospital of the University of Pennsylvania, Philadelphia, took the plunge and began using DBT for every breast screening patient, regardless of age, cancer risk, breast density, or ability to pay.

Over a 17-month-period, DBT detected 82 cancers in 15,632 women, or 5.25 cancers per 1,000 cases, Dr. Emily F. Conant reported at the annual meeting of the Radiological Society of North America.

This compares with 46 cancers, or 4.28 cancers per 1,000 cases, detected with conventional mammography in 10,752 women in the 12 months prior to the switch.

The difference in cancer detection rates between 2D and 3D mammography did not reach statistical significance (P = .226), probably because of the small number of cases, Dr. Conant, a radiology professor at the hospital, said at a press briefing.

Compared with conventional mammography, however, DBT significantly improved the proportion of positive screening mammograms from which cancer was diagnosed by 45% (P = .036) and increased the detection of deadly invasive cancers by a nonsignificant 31%.

When asked whether the study showed that invasive lobular cancer can be better detected with DBT, Dr. Conant replied, "Yes. Those were the most remarkable cases, because those tumors tend to be large at presentation and notoriously difficult to detect because they don’t often form the mass that an invasive ductal carcinoma does."

Press briefing moderator Dr. Debra L. Somers Copit, chief of mammography and director of the Gershon-Cohen Breast Clinic at Einstein Medical Center, Philadelphia, described the improvements in cancer detection in the real-world cohort as "groundbreaking work for this modality that we hope will pan out across multiple institutions."

Reimbursement is problematic, however, as insurers will only pay for 2D mammography images taken as part of a tomosynthesis screening exam, she said in an interview.

Still, she personally believes tomosynthesis should now be the standard of care, adding, "I can’t imagine reading a mammogram without it."

Results from the current study are comparable with data reported recently from trials in the United States (Radiology 2013;269:694-700) and Norway (Eur. Radiol. 2013;23:2061-71) that paired 2D imaging with 3D tomosynthesis, Dr. Conant observed.

When the investigators looked at the independent risk factor of breast density, DBT also did a better job of detecting cancer than conventional mammography in fatty, scattered, heterogeneous, and extremely dense breasts, and it improved recall rates for all categories except extremely dense breasts, she said.

Overall, DBT significantly reduced the proportion of women recalled for additional imaging from 10.39% to 8.77% (P = .001).

DBT is an exciting improvement over 2D mammography and more economical than breast screening with magnetic resonance imaging, but it is "not the solution to everything," Dr. Conant said. The radiation dose for the average breast is within safety limits, but twice that of a regular mammogram.

"The cost to the patient is not monetary at our site; it may be at other sites," she said. "I think right now the dose is the biggest cost."

The May 2013 approval of Hologic’s C-View 2D imaging software, which eliminates the need for additional 2D exposures by generating 2D images from 3D tomosynthesis data, might address this, Dr. Conant added.

Dr. Conant reported consulting for Hologic. Her coauthors reported no financial disclosures. Dr. Copit is on Hologic’s scientific advisory board.

pwendling@frontlinemedcom.com

CHICAGO – Screening all-comers with three-dimensional mammography increased breast cancer detection by 22.7% and reduced recall rates by 15.6% in a large observational study.

Although a 3D digital breast tomosynthesis (DBT) system was approved for breast cancer screening and diagnosis in the United States in 2011, DBT is typically a supplemental screening tool to standard 2D digital mammography.

In November 2011, however, the Hospital of the University of Pennsylvania, Philadelphia, took the plunge and began using DBT for every breast screening patient, regardless of age, cancer risk, breast density, or ability to pay.

Over a 17-month-period, DBT detected 82 cancers in 15,632 women, or 5.25 cancers per 1,000 cases, Dr. Emily F. Conant reported at the annual meeting of the Radiological Society of North America.

This compares with 46 cancers, or 4.28 cancers per 1,000 cases, detected with conventional mammography in 10,752 women in the 12 months prior to the switch.

The difference in cancer detection rates between 2D and 3D mammography did not reach statistical significance (P = .226), probably because of the small number of cases, Dr. Conant, a radiology professor at the hospital, said at a press briefing.

Compared with conventional mammography, however, DBT significantly improved the proportion of positive screening mammograms from which cancer was diagnosed by 45% (P = .036) and increased the detection of deadly invasive cancers by a nonsignificant 31%.

When asked whether the study showed that invasive lobular cancer can be better detected with DBT, Dr. Conant replied, "Yes. Those were the most remarkable cases, because those tumors tend to be large at presentation and notoriously difficult to detect because they don’t often form the mass that an invasive ductal carcinoma does."

Press briefing moderator Dr. Debra L. Somers Copit, chief of mammography and director of the Gershon-Cohen Breast Clinic at Einstein Medical Center, Philadelphia, described the improvements in cancer detection in the real-world cohort as "groundbreaking work for this modality that we hope will pan out across multiple institutions."

Reimbursement is problematic, however, as insurers will only pay for 2D mammography images taken as part of a tomosynthesis screening exam, she said in an interview.

Still, she personally believes tomosynthesis should now be the standard of care, adding, "I can’t imagine reading a mammogram without it."

Results from the current study are comparable with data reported recently from trials in the United States (Radiology 2013;269:694-700) and Norway (Eur. Radiol. 2013;23:2061-71) that paired 2D imaging with 3D tomosynthesis, Dr. Conant observed.

When the investigators looked at the independent risk factor of breast density, DBT also did a better job of detecting cancer than conventional mammography in fatty, scattered, heterogeneous, and extremely dense breasts, and it improved recall rates for all categories except extremely dense breasts, she said.

Overall, DBT significantly reduced the proportion of women recalled for additional imaging from 10.39% to 8.77% (P = .001).

DBT is an exciting improvement over 2D mammography and more economical than breast screening with magnetic resonance imaging, but it is "not the solution to everything," Dr. Conant said. The radiation dose for the average breast is within safety limits, but twice that of a regular mammogram.

"The cost to the patient is not monetary at our site; it may be at other sites," she said. "I think right now the dose is the biggest cost."

The May 2013 approval of Hologic’s C-View 2D imaging software, which eliminates the need for additional 2D exposures by generating 2D images from 3D tomosynthesis data, might address this, Dr. Conant added.

Dr. Conant reported consulting for Hologic. Her coauthors reported no financial disclosures. Dr. Copit is on Hologic’s scientific advisory board.

pwendling@frontlinemedcom.com

New results from the Neo ALTTO, I-SPY 2, and IBIS-II trials will head up our onsite coverage of the San Antonio Breast Cancer Symposium, to be held Dec. 10-14.

Survival follow-up analysis of the Neo ALTTO study (BIG 1-06)

Reports on new therapies in the neoadjuvant setting at SABCS will include the latest survival follow-up analysis from the Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization) study. The results examine the association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab, or their combination in HER2-positive breast cancer.

To put the new findings in perspective, read our prior report on Neo ALTTO as well as a study that examined the effect of Neo ALTTO findings on treatment decisions.

Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer

First results from the I-SPY 2 trial will examine whether adding experimental agents to standard neoadjuvant medications increases the probability of pathologic complete response over standard neoadjuvant chemotherapy for specific biomarker signatures established at trial entry.

Anastrozole as preventive therapy in postmenopausal women at increased risk of breast cancer

First results of the IBIS-II (International Breast Cancer Intervention Study II) trial will examine the outcomes of women who were at high risk for breast cancer and given either anastrozole or placebo. Guidelines on preventive therapy, issued earlier this year by the U.S. Preventive Services Task Force, did not include recommendations regarding the aromatase inhibitor anastrozole, pending the data from the IBIS-II trial.

Look for your newsletters featuring these reports and our insightful video interviews with researchers who put the findings into perspective for your practice. Our next-best-thing-to-being-there coverage of SABCS begins on Dec. 10.

New results from the Neo ALTTO, I-SPY 2, and IBIS-II trials will head up our onsite coverage of the San Antonio Breast Cancer Symposium, to be held Dec. 10-14.

Survival follow-up analysis of the Neo ALTTO study (BIG 1-06)

Reports on new therapies in the neoadjuvant setting at SABCS will include the latest survival follow-up analysis from the Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization) study. The results examine the association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab, or their combination in HER2-positive breast cancer.

To put the new findings in perspective, read our prior report on Neo ALTTO as well as a study that examined the effect of Neo ALTTO findings on treatment decisions.

Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer

First results from the I-SPY 2 trial will examine whether adding experimental agents to standard neoadjuvant medications increases the probability of pathologic complete response over standard neoadjuvant chemotherapy for specific biomarker signatures established at trial entry.

Anastrozole as preventive therapy in postmenopausal women at increased risk of breast cancer

First results of the IBIS-II (International Breast Cancer Intervention Study II) trial will examine the outcomes of women who were at high risk for breast cancer and given either anastrozole or placebo. Guidelines on preventive therapy, issued earlier this year by the U.S. Preventive Services Task Force, did not include recommendations regarding the aromatase inhibitor anastrozole, pending the data from the IBIS-II trial.

Look for your newsletters featuring these reports and our insightful video interviews with researchers who put the findings into perspective for your practice. Our next-best-thing-to-being-there coverage of SABCS begins on Dec. 10.

New results from the Neo ALTTO, I-SPY 2, and IBIS-II trials will head up our onsite coverage of the San Antonio Breast Cancer Symposium, to be held Dec. 10-14.

Survival follow-up analysis of the Neo ALTTO study (BIG 1-06)

Reports on new therapies in the neoadjuvant setting at SABCS will include the latest survival follow-up analysis from the Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization) study. The results examine the association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab, or their combination in HER2-positive breast cancer.

To put the new findings in perspective, read our prior report on Neo ALTTO as well as a study that examined the effect of Neo ALTTO findings on treatment decisions.

Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer

First results from the I-SPY 2 trial will examine whether adding experimental agents to standard neoadjuvant medications increases the probability of pathologic complete response over standard neoadjuvant chemotherapy for specific biomarker signatures established at trial entry.

Anastrozole as preventive therapy in postmenopausal women at increased risk of breast cancer

First results of the IBIS-II (International Breast Cancer Intervention Study II) trial will examine the outcomes of women who were at high risk for breast cancer and given either anastrozole or placebo. Guidelines on preventive therapy, issued earlier this year by the U.S. Preventive Services Task Force, did not include recommendations regarding the aromatase inhibitor anastrozole, pending the data from the IBIS-II trial.

Look for your newsletters featuring these reports and our insightful video interviews with researchers who put the findings into perspective for your practice. Our next-best-thing-to-being-there coverage of SABCS begins on Dec. 10.